MUHAS IR Home
→
School of Pharmacy
→
Browsing School of Pharmacy by Author

Browsing School of Pharmacy by Author "Aklillu, E."

Now showing items 1-6 of 6

Comparison of malaria treatment outcome of generic and innovator’s anti‑malarial drugs containing artemether– lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children

Kilonzi, M; Minzi, O; Mutagonda, R; Sasi, P.; Kamuhabwa, A.; Aklillu, E. (BMC, 2019)

Abstract Background: In 2006, artemether–lumefantrine (ALU), specifically Coartem ® (Novartis Pharma AG, Basel Switzerland), was approved as the first-line drug for treatment of uncomplicated malaria in Tanzania. Due ...
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection

Minzi, O. M; Mnkugwe, R. H.; Ngaimisi, E.; Kinung’hi, S.; Hansson, A.; Pohanka, A; Kamuhabwa, A.; Aklillu, E. (MDPI-Pharmaceuticals, 2021)

Praziquantel (PZQ) and dihydroartemisinin-piperaquine (DHP) combination recently showed superior effectiveness than PZQ alone to treat intestinal schistosomiasis. In this follow-up study, we investigated the effect of ...
Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial

Mlugu, E. M.; Minzi, O.; Kamuhabwa, A. A. R.; Aklillu, E. (Clinical Pharmacology & Therapeutics, 2021)

Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) to prevent malaria and adverse birth outcomes is threatened by Plasmodium falciparum resistance to sulfadoxine-pyrimethamine. We ...
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment

Maganda, A.B.; Ngaimisi, E.; Kamuhabwa, R.A.; Aklillu, E.; Minzi, M.O (Beo med central, 2015-04)

Background: HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART). EFV, ...
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin

Mugusi, S; Ngaimisi, E.; Mugusi, F.; Minzi, O; Aris, E.; Bertilsson, L.; Burhenne, J.; Sandstrom, E.; Aklillu, E.; Anabi, M. (Springer, 2018)

Purpose Efavirenz-based combination antiretroviral therapy (cART) is associated with neuropsychiatric adverse events. We investigated the time to onset, duration, clinical implications, impact of pharmacogenetic variations, ...
Optimal single sampling time‑point for monitoring of praziquantel exposure in children

Mnkugwe, R. H.; Kitabi, E. N.; Kinung’hi, S.; Kamuhabwa, A. A. R.; Minzi, O. M.; Aklillu, E. (Scientific Reports, 2021)

Praziquantel pharmacokinetics studies in schistosomiasis infected children are scarce partly due to the challenges/complexity of intensive blood sampling in the target population. This study was aimed to investigate ...

Now showing items 1-6 of 6

Search MUHAS IR

Advanced Search

Browse

All of MUHAS IR
This Community
- By Issue Date
- Authors
- Titles
- Subjects

Browsing School of Pharmacy by Author "Aklillu, E."

Browsing School of Pharmacy by Author "Aklillu, E."

Search MUHAS IR

Browse

All of MUHAS IR

This Community

My Account